HC Wainwright began coverage on shares of MannKind Corporation (NASDAQ:MNKD) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the company. Maxim Group restated a “buy” rating on shares of MannKind Corporation in a research note on Friday, September 1st. Zacks Investment Research cut MannKind Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, ValuEngine cut MannKind Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $0.92.

MannKind Corporation (NASDAQ:MNKD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10). The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $2.75 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. During the same quarter in the previous year, the firm posted $0.08 EPS.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/10/hc-wainwright-begins-coverage-on-mannkind-corporation-mnkd.html.

Institutional investors have recently made changes to their positions in the company. KCG Holdings Inc. raised its stake in shares of MannKind Corporation by 268.0% during the 1st quarter. KCG Holdings Inc. now owns 147,952 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 107,752 shares in the last quarter. LMR Partners LLP bought a new stake in shares of MannKind Corporation during the 2nd quarter worth approximately $352,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of MannKind Corporation by 20.1% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 588,520 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 98,520 shares in the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in shares of MannKind Corporation during the 2nd quarter worth approximately $568,000. Institutional investors own 15.67% of the company’s stock.

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.